Arcus biosciences announces new employment inducement grants

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the compensation committee of the company's board of directors granted one new employee options to purchase a total of 2,850 shares of the company's common stock at an exercise price per share of $8.63, which was the closing price on june 23, 2025, and restri.
RCUS Ratings Summary
RCUS Quant Ranking